Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangxi Wuzhou Zhongheng Group Co (SHSE:600252) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Guangxi Wuzhou Zhongheng Group Co EBITDA Margin % Related Terms
Guangxi Wuzhou Zhongheng Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangxi Wuzhou Zhongheng Group Co EBITDA Margin % Chart
SHSE:600252 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Guangxi Wuzhou Zhongheng Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangxi Wuzhou Zhongheng Group Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guangxi Wuzhou Zhongheng Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Guangxi Wuzhou Zhongheng Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangxi Wuzhou Zhongheng Group Co (SHSE:600252) has a EBITDA Margin % of -7.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guangxi Wuzhou Zhongheng Group Co and its competitors. According to the industry distribution chart, Guangxi Wuzhou Zhongheng Group Co ranks #831 out of 961 companies in the Drug Manufacturers industry, placing it in the top 86.5%.
Is Guangxi Wuzhou Zhongheng Group Co's EBITDA Margin % too high?
Guangxi Wuzhou Zhongheng Group Co's current EBITDA Margin % is -7.94%. Based on the distribution chart, Guangxi Wuzhou Zhongheng Group Co ranks #831 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Guangxi Wuzhou Zhongheng Group Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guangxi Wuzhou Zhongheng Group Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guangxi Wuzhou Zhongheng Group Co ranks #831 out of 961 companies for EBITDA Margin %. This places Guangxi Wuzhou Zhongheng Group Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guangxi Wuzhou Zhongheng Group Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangxi Wuzhou Zhongheng Group Co's current EBITDA Margin % is -7.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangxi Wuzhou Zhongheng Group Co stock overvalued right now?
Based on GuruFocus' analysis, Guangxi Wuzhou Zhongheng Group Co (SHSE:600252) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.57, compared to a current price of ¥2.15 — trading 36.9% above its estimated fair value. The current EBITDA Margin % is -7.94%. Guangxi Wuzhou Zhongheng Group Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guangxi Wuzhou Zhongheng Group Co (SHSE:600252), the current EBITDA Margin % is -7.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangxi Wuzhou Zhongheng Group Co (SHSE:600252) Overvalued in 2026?
Based on GuruFocus' analysis, Guangxi Wuzhou Zhongheng Group Co stock appears to be overvalued.
The current stock price of ¥2.15 is trading 36.9% above its estimated GF Value™ of ¥1.57.
GuruFocus considers Guangxi Wuzhou Zhongheng Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600252:
EBITDA Margin %: -7.94%
GF Value™: ¥1.57 vs. price of ¥2.15 (36.9% above fair value)
No single metric tells the full story. See the SHSE:600252 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangxi Wuzhou Zhongheng Group Co Business Description
Guangxi Wuzhou Zhongheng Group Co Ltd is a Chinese company engaged in the production of Chinese medicines. The company is also involved in real estate and health foods.
39GF Score
Get the complete analysis for SHSE:600252
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600252 has been successfully added to your 
